Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. TNYA
stocks logo

TNYA

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.149
-46.88%
--
--
-0.140
-41.67%
--
--
-0.140
-0%
Estimates Revision
The market is revising No Change the revenue expectations for Tenaya Therapeutics, Inc. (TNYA) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 2.22%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-5.59%
In Past 3 Month
Stock Price
Go Up
up Image
+2.22%
In Past 3 Month
Wall Street analysts forecast TNYA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TNYA is 11.33 USD with a low forecast of 3.00 USD and a high forecast of 40.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
Wall Street analysts forecast TNYA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TNYA is 11.33 USD with a low forecast of 3.00 USD and a high forecast of 40.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.380
sliders
Low
3.00
Averages
11.33
High
40.00
Current: 1.380
sliders
Low
3.00
Averages
11.33
High
40.00
HC Wainwright & Co.
Joseph Pantginis
Strong Buy
Reiterates
$5
2025-03-31
Reason
HC Wainwright & Co.
Joseph Pantginis
Price Target
$5
2025-03-31
Reiterates
Strong Buy
Reason
Canaccord Genuity
Whitney Ijem
Strong Buy
Maintains
$18 → $6
2025-03-13
Reason
Canaccord Genuity
Whitney Ijem
Price Target
$18 → $6
2025-03-13
Maintains
Strong Buy
Reason
Canaccord analyst Whitney Ijem lowered the firm's price target on Tenaya Therapeutics to $6 from $18 and keeps a Buy rating on the shares. The firm said its 4Q24 earnings report was straightforward, with the more notable news coming earlier in December with the announcement of positive clinical data from cohort 1 of TN-201's Ph1b/2 (MyPeak-1) for the treatment of MYBPC3-associated HCM.
Chardan Capital
Geulah Livshits
Strong Buy
Maintains
$18 → $9
2025-03-12
Reason
Chardan Capital
Geulah Livshits
Price Target
$18 → $9
2025-03-12
Maintains
Strong Buy
Reason
Chardan lowered the firm's price target on Tenaya Therapeutics to $9 from $18 and keeps a Buy rating on the shares. The firm's updated model incorporates equity dilution from the March offering and reflects its reduced assumptions regarding earlier stage pipeline programs for the company, the analyst tells investors in a research note.
Morgan Stanley
Matthew Harrison
Buy
Maintains
$15 → $5
2025-03-12
Reason
Morgan Stanley
Matthew Harrison
Price Target
$15 → $5
2025-03-12
Maintains
Buy
Reason
HC Wainwright & Co.
Joseph Pantginis
Strong Buy
Maintains
$18 → $5
2025-03-11
Reason
HC Wainwright & Co.
Joseph Pantginis
Price Target
$18 → $5
2025-03-11
Maintains
Strong Buy
Reason
HC Wainwright & Co.
Emily Bodnar
Strong Buy
Reiterates
$18
2025-02-03
Reason
HC Wainwright & Co.
Emily Bodnar
Price Target
$18
2025-02-03
Reiterates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Tenaya Therapeutics Inc (TNYA.O) is -2.43, compared to its 5-year average forward P/E of -2.68. For a more detailed relative valuation and DCF analysis to assess Tenaya Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-2.68
Current PE
-2.43
Overvalued PE
-0.37
Undervalued PE
-4.99

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-1.94
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
1.55
Undervalued EV/EBITDA
-5.43

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
63.48
Current PS
0.00
Overvalued PS
202.11
Undervalued PS
-75.15
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

TNYA News & Events

Events Timeline

(ET)
2025-11-10
07:01:36
Tenaya Therapeutics announces Q3 earnings per share of 12 cents, below consensus estimate of 15 cents.
select
2025-11-09 (ET)
2025-11-09
13:13:26
Tenaya Therapeutics unveils updated interim safety and efficacy results for TN-201
select
2025-08-06 (ET)
2025-08-06
18:09:23
Tenaya Therapeutics reports Q2 EPS (14c), consensus (19c)
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
11-09Newsfilter
Tenaya Therapeutics Unveils Encouraging Interim Results from MYPEAK™-1 Phase 1b/2a Trial of TN-201 Gene Therapy for MYBPC3-Related Hypertrophic Cardiomyopathy

  • MyPEAK-1 Clinical Trial Results: Interim data from Tenaya Therapeutics' MyPEAK-1 Phase 1b/2a trial of TN-201 gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (HCM) showed promising safety and efficacy, with significant improvements in hypertrophy and heart failure symptoms among patients.

  • Safety and Tolerability: TN-201 was generally well tolerated at both tested doses, with no dose-limiting toxicities reported. The most common adverse events were reversible liver enzyme elevations, and no cardiotoxicities were observed.

  • Biomarker Improvements: Patients in Cohort 1 exhibited substantial decreases in cardiac biomarkers and left ventricular hypertrophy, with improvements in NYHA classification indicating better heart failure symptom management.

  • Future Plans and Webcast: Tenaya plans to continue long-term follow-up of trial participants and will host a conference call on November 10, 2025, to discuss the trial's findings and next steps for TN-201's development.

[object Object]
Preview
9.0
11-08SeekingAlpha
Tenaya Therapeutics Shares Decline Following FDA's Clinical Hold on Heart Disorder Study

  • FDA Clinical Hold: Tenaya Therapeutics' stock dropped 16% after the FDA placed a clinical hold on its mid-stage trial for TN-201, which targets MYBPC3-associated hypertrophic cardiomyopathy, due to requested changes in the trial protocol.

  • Protocol Modifications: The FDA's request aims to ensure consistent patient monitoring and management of immunosuppression across trial sites, following discussions about the TN-201 program and data reviewed by the independent Data Safety Monitoring Board.

  • Impact on Development: Despite the clinical hold, Tenaya Therapeutics does not expect any impact on the data milestones or development timelines for TN-201.

  • Future Data Releases: Tenaya is scheduled to present data on two heart disorders in Q4 2025, which is anticipated to be a significant inflection point for the company.

[object Object]
Preview
9.0
11-05Newsfilter
Tenaya Therapeutics to Present New Clinical Data on TN-201 Gene Therapy in Late-Breaking Session at the 2025 American Heart Association Scientific Sessions

  • Upcoming Presentations: Tenaya Therapeutics will present interim safety and efficacy results from the MyPEAK-1 Phase 1b/2a clinical trial for TN-201, a gene therapy for MYBPC3-associated hypertrophic cardiomyopathy, at the AHA 2025 Scientific Sessions on November 8, 2025.

  • Preclinical Study Results: A second presentation will showcase results from a preclinical study on cellular reprogramming gene therapy in a pig model of ischemic heart failure, scheduled for November 9, 2025.

  • Webcast Conference Call: Tenaya management will host a conference call on November 10, 2025, to discuss the TN-201 data presented at the AHA sessions, accessible via their investor website.

  • Company Overview: Tenaya Therapeutics focuses on developing potentially curative therapies for heart disease, with a pipeline that includes gene therapies for various cardiomyopathies and heart failure treatments.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Tenaya Therapeutics Inc (TNYA) stock price today?

The current price of TNYA is 1.38 USD — it has increased 3.76 % in the last trading day.

arrow icon

What is Tenaya Therapeutics Inc (TNYA)'s business?

Tenaya Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. Its pipeline includes TN-201, TN-401, and TN-301. TN-201 is an adeno-associated virus serotype 9 (AAV9)-based gene therapy designed to deliver a working MYBPC3 gene to heart muscle cells via a single intravenous infusion, increasing MyBP-C protein levels to address the underlying cause of MYBPC3-associated HCM with the aim of halting or even reversing disease after a single dose. Its MyPEAK-1 Phase I b/2 clinical trial is an ongoing, multi-center, open-label, dose-escalating study designed to assess the safety, tolerability and clinical efficacy of a one-time intravenous infusion of TN-201 gene replacement therapy. TN-401 is its AAV9-based gene therapy being developed for the treatment of arrhythmogenic right ventricular cardiomyopathy (ARVC) due to disease-causing variants in the PKP2 gene.

arrow icon

What is the price predicton of TNYA Stock?

Wall Street analysts forecast TNYA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TNYA is 11.33 USD with a low forecast of 3.00 USD and a high forecast of 40.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Tenaya Therapeutics Inc (TNYA)'s revenue for the last quarter?

Tenaya Therapeutics Inc revenue for the last quarter amounts to -20.94M USD, decreased -21.62 % YoY.

arrow icon

What is Tenaya Therapeutics Inc (TNYA)'s earnings per share (EPS) for the last quarter?

Tenaya Therapeutics Inc. EPS for the last quarter amounts to -15625000.00 USD, decreased -21.95 % YoY.

arrow icon

What changes have occurred in the market's expectations for Tenaya Therapeutics Inc (TNYA)'s fundamentals?

The market is revising No Change the revenue expectations for Tenaya Therapeutics, Inc. (TNYA) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 2.22%.
arrow icon

How many employees does Tenaya Therapeutics Inc (TNYA). have?

Tenaya Therapeutics Inc (TNYA) has 97 emplpoyees as of December 05 2025.

arrow icon

What is Tenaya Therapeutics Inc (TNYA) market cap?

Today TNYA has the market capitalization of 229.78M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free